Drug Trial Radar · NCT07059312
A Phase 1 Study of JADE101 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Aug 17, 2025
Primary completion
Oct 21, 2026
Study completion Oct 21, 2026
Sponsor
- Lead sponsor
- Jade Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.
Conditions
- Healthy Volunteers
Interventions
JADE101Drug
JADE101 is supplied as sterile solution to be administered by SC injection.
PlaceboDrug
Placebo solution to be administered at a matching volume by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy ParticipantsTime frame: Day 1 through 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NZCR
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.